BC Extra | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
BC Week In Review | Aug 19, 2013
Clinical News

Civacir: Phase III started

Biotest began the open-label, North American Phase III Study 988 to evaluate 200 and 300 mg/kg Civacir in up to 90 patients. Patients will receive Civacir starting on the day of liver transplant, but prior...
BC Week In Review | Dec 3, 2012
Clinical News

Inavir laninamivir regulatory update

Daiichi submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) to expand the label for Inavir laninamivir dry powder inhaler to include the prevention of influenza infection. The second-generation, long-acting neuraminidase...
BC Week In Review | Nov 12, 2012
Company News

Biota, Nabi deal

The partners completed their merger. Prior to the completion, Nabi implemented a one-for-six reverse stock split. The company then changed its name to Biota Pharmaceuticals Inc. and began trading on NASDAQ on Nov. 9 under...
BC Week In Review | Oct 29, 2012
Company News

Biota, Nabi deal

Nabi and Biota set the exchange ratio in the companies' proposed merger via a stock deal. Nabi will acquire all of Biota Holdings' shares at a rate of about 0.125 new Nabi shares for one...
BC Week In Review | Oct 22, 2012
Clinical News

NicVax: Preliminary Phase II data

Preliminary data from a double-blind, Dutch Phase II trial in 558 patients showed that NicVax plus Chantix varenicline missed the primary endpoint of improving abstinence rate at 12 months as measured from week 9 through...
BC Week In Review | Oct 1, 2012
Company News

Nabi infectious, neurology news

Nabi adjourned a special shareholders meeting, during which shareholders were to vote on the proposed merger of Nabi and Biota Holdings Ltd. (ASX:BTA, Notting Hill, Australia), due to an absence of quorum. The meeting will...
BC Week In Review | Sep 24, 2012
Company News

Biota, Nabi deal

The companies amended an April agreement to merge in a stock deal to address Biota's share price decline since the deal was first announced. Nabi will now contribute $27 million in cash to the combined...
BC Week In Review | Aug 27, 2012
Clinical News

Inavir laninamivir: Phase III data

A double-blind, Japanese Phase III trial in >1,500 healthy family members of a patient with confirmed influenza infection A or B infection showed that both dose regimens of Inavir met the primary endpoint of reducing...
BC Week In Review | Aug 20, 2012
Company News

Nabi infectious, neurology news

Investor Mangrove Partners Fund L.P. sent a letter to Nabi shareholders recommending that shareholders vote against the proposed merger of Nabi and Biota Holdings Ltd. (ASX:BTA, Notting Hill, Australia). The vote is scheduled for Sept....
Items per page:
1 - 10 of 416
BC Extra | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
BC Week In Review | Aug 19, 2013
Clinical News

Civacir: Phase III started

Biotest began the open-label, North American Phase III Study 988 to evaluate 200 and 300 mg/kg Civacir in up to 90 patients. Patients will receive Civacir starting on the day of liver transplant, but prior...
BC Week In Review | Dec 3, 2012
Clinical News

Inavir laninamivir regulatory update

Daiichi submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) to expand the label for Inavir laninamivir dry powder inhaler to include the prevention of influenza infection. The second-generation, long-acting neuraminidase...
BC Week In Review | Nov 12, 2012
Company News

Biota, Nabi deal

The partners completed their merger. Prior to the completion, Nabi implemented a one-for-six reverse stock split. The company then changed its name to Biota Pharmaceuticals Inc. and began trading on NASDAQ on Nov. 9 under...
BC Week In Review | Oct 29, 2012
Company News

Biota, Nabi deal

Nabi and Biota set the exchange ratio in the companies' proposed merger via a stock deal. Nabi will acquire all of Biota Holdings' shares at a rate of about 0.125 new Nabi shares for one...
BC Week In Review | Oct 22, 2012
Clinical News

NicVax: Preliminary Phase II data

Preliminary data from a double-blind, Dutch Phase II trial in 558 patients showed that NicVax plus Chantix varenicline missed the primary endpoint of improving abstinence rate at 12 months as measured from week 9 through...
BC Week In Review | Oct 1, 2012
Company News

Nabi infectious, neurology news

Nabi adjourned a special shareholders meeting, during which shareholders were to vote on the proposed merger of Nabi and Biota Holdings Ltd. (ASX:BTA, Notting Hill, Australia), due to an absence of quorum. The meeting will...
BC Week In Review | Sep 24, 2012
Company News

Biota, Nabi deal

The companies amended an April agreement to merge in a stock deal to address Biota's share price decline since the deal was first announced. Nabi will now contribute $27 million in cash to the combined...
BC Week In Review | Aug 27, 2012
Clinical News

Inavir laninamivir: Phase III data

A double-blind, Japanese Phase III trial in >1,500 healthy family members of a patient with confirmed influenza infection A or B infection showed that both dose regimens of Inavir met the primary endpoint of reducing...
BC Week In Review | Aug 20, 2012
Company News

Nabi infectious, neurology news

Investor Mangrove Partners Fund L.P. sent a letter to Nabi shareholders recommending that shareholders vote against the proposed merger of Nabi and Biota Holdings Ltd. (ASX:BTA, Notting Hill, Australia). The vote is scheduled for Sept....
Items per page:
1 - 10 of 416